Geisinger Health System announced it is partnering with machine learning solution provider EarlySign to develop AI-based solutions to identify individuals at risk of a range of chronic and high-burden diseases. The multi-year agreement will begin by deploying EarlySign’s LGI Flag through Geisinger’s Steele Institute for Health Innovation – to identify patients at risk of lower gastrointestinal conditions – including colorectal cancer and precancerous adenomas. This partnership follows the successful implementation of EarlySign’s AI solutions in North America with SLUCare and Kaiser Permanente.
EarlySign’s LGI Flag
LGI-Flag is an advanced software solution that analyzes medical data –including changes in routine blood tests – to flag individuals who will benefit from further evaluation. Reflecting the Steele Institute’s efforts to transform healthcare delivery by implementing solutions that improve health, patient experience, care delivery, and affordability, the partnership will also explore additional opportunities to benefit patients and their care providers.
LGI-Flag has been used in healthcare systems around the world since 2015 to identify patients at risk for lower GI disorders associated with chronic occult bleeding. The technology will form the basis for Geisinger and EarlySign to address similar opportunities with other acute and chronic diseases. The partnership will benefit from Geisinger’s innovation infrastructure, unique data assets, and world-class care teams.
“Leveraging Geisinger’s performance as a national leader in healthcare and its culture of innovation with EarlySign’s expertise in machine learning and data analytics will enable us to identify, evaluate and intervene with high-risk patients earlier,” said Karen Murphy, Ph.D., Executive Vice President and Chief Innovation Officer at Geisinger. “This collaboration will help us potentially save lives and improve the care we provide patients by deepening our experience with AI and identifying new ways to integrate it into daily clinical care.”
